GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) have helped millions of people lose weight and control their blood sugar. But like all medications, they can have side effects — and one of the more overlooked ones is an increased risk of gallstones and gallbladder inflammation.
This isn't a one-in-a-million complication. Studies show a real, if modest, increase in risk. This article explains what happens in the body, what the research shows, and what you can practically do about it.
What is the gallbladder?
The gallbladder is a small, pear-shaped pouch that sits beneath your liver on the right side of your abdomen. Its job is simple: it collects and concentrates bile — a yellow-green fluid that the liver produces to help break down fat in the small intestine.
When you eat a fatty meal, your intestine sends a signal to the gallbladder to contract and release bile into the duodenum. The key messenger in this process is the hormone cholecystokinin (CCK). Without sufficient CCK activity, the gallbladder empties more slowly — and that is where GLP-1 medications enter the picture.
How do gallstones form?
Gallstones form when the bile inside the gallbladder becomes unbalanced. The most common type — cholesterol gallstones — develop when bile contains too much cholesterol relative to the substances that keep it dissolved (bile salts and lecithin).
Overly concentrated bile that sits too long gradually crystallises. Over time, the crystals grow into stones that can range from the size of a grain of sand to a golf ball. Many people have gallstones and never know it — they cause no symptoms at all. But if a stone blocks the gallbladder's outlet, it can cause severe pain and, in serious cases, inflammation (cholecystitis).
Why does GLP-1 medication increase the risk?
Research points to two interacting mechanisms:
Mechanism 1: Slower gallbladder emptying
GLP-1 receptors are found not just in the brain and pancreas — they also exist in the gastrointestinal tract, including in the nerve pathways that control gallbladder motility. When GLP-1 medications activate these receptors, they inhibit the release of cholecystokinin (CCK). The result is that the gallbladder contracts less frequently and empties more slowly.
Bile that lingers too long in the gallbladder becomes concentrated and can crystallise. That is exactly the environment in which gallstones thrive.
Mechanism 2: Rapid weight loss
Rapid weight loss is itself a well-established risk factor for gallstones — regardless of whether it comes from dieting, bariatric surgery, or medication. When the body burns fat quickly, the liver secretes more cholesterol into bile, and the bile becomes supersaturated. This significantly increases the likelihood of crystal formation.
GLP-1 medications are highly effective at promoting weight loss — and this is likely the single most important driver of the elevated gallstone risk, particularly for people who lose weight quickly in the first few months of treatment.
What do the studies show?
The research is clear: GLP-1 medications increase the risk of biliary events.
A large meta-analysis published in JAMA Internal Medicine in 2022 reviewed data from multiple clinical trials and found that GLP-1 receptor agonists increased the risk of gallstones by approximately 27% (relative risk 1.27) and the risk of gallbladder inflammation by approximately 36% (relative risk 1.37) compared to placebo.
In absolute terms, the picture is more reassuring. In semaglutide trials, approximately 1.6% of participants developed gallstones compared to about 0.7% in the placebo group over the study period. This means the vast majority — more than 98 out of 100 — did not develop gallstones.
Based on this evidence, the FDA has included a formal warning about gallbladder events in the official prescribing information for Wegovy (semaglutide 2.4 mg).
What are the symptoms?
Gallstones don't always cause symptoms — many people discover them incidentally during an unrelated scan. When they do cause symptoms, these are typical:
- Pain under the right ribs — often intense, cramping pain that comes on suddenly, especially after a fatty meal.
- Pain that radiates — to the right shoulder or the back beneath the shoulder blade.
- Nausea and vomiting — particularly during pain episodes.
- Fever and chills — these symptoms suggest gallbladder inflammation (cholecystitis) and require prompt medical attention.
- Yellowing of skin or eyes (jaundice) — occurs if a stone blocks the bile duct leading to the intestine.
A pain episode typically lasts 30 minutes to a few hours. Fever and persistent pain are warning signs of a complication that needs urgent treatment.
What can you do?
You don't need to stop your medication out of fear of gallstones — but there are steps you can take to reduce your risk:
- Avoid very high-fat meals. Fat is the strongest trigger for gallbladder contractions. A diet with moderate fat (not zero fat — the gallbladder still needs to empty regularly) reduces the burden.
- Lose weight gradually. A weight loss rate of around 0.5–1 kg (1–2 lb) per week is considered safe from a gallstone perspective. Very rapid loss increases risk. Talk to your doctor if you are losing weight very quickly.
- Stay well hydrated. Adequate fluid intake helps keep bile from becoming overly concentrated.
- Ask your doctor about ursodiol. In specific circumstances — such as very rapid weight loss — bile acid medication (ursodeoxycholic acid) can be considered for prevention. This is not a standard recommendation but may be relevant for higher-risk individuals.
If gallstones are already diagnosed, treatment ranges from watchful waiting (no symptoms, no intervention) to dietary adjustments to surgery. Laparoscopic removal of the gallbladder (cholecystectomy) is a routine procedure with a short recovery and good outcomes.
Is the risk the same for all GLP-1 medications?
Not necessarily. Some analyses suggest there may be differences between individual drugs.
Tirzepatide (Mounjaro) — which activates both GIP and GLP-1 receptors — appears in certain analyses to carry a lower gallbladder risk than semaglutide. One possible explanation is that the GIP component influences gallbladder motility differently from pure GLP-1 stimulation. Research in this area is still ongoing, however, and head-to-head comparisons are difficult because the trials were not designed identically.
What all GLP-1 medications share is that risk scales with the speed of weight loss. Regardless of which medication you take, a steady, controlled rate of weight loss is preferable to a very rapid one.
When should you seek help?
Contact your doctor if you experience:
- Recurring pain on the right side of your abdomen, especially after fatty meals
- Nausea and vomiting that is not explained by the usual GLP-1-related nausea (which is typically mild and fades over time)
Seek urgent medical care if you develop:
- Severe abdominal pain combined with fever
- Yellowing of skin or eyes
- Pain that persists for more than a few hours without easing
Gallbladder inflammation can in rare cases escalate quickly — it is not something to wait out overnight.